EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Graves’ hyperthyroidism treated with potassium iodide: early response and after 2 years of follow-up

Megumi Fujikawa iD, Ken Okamura

European Thyroid Journal · 2024

DOI: 10.1530/etj-24-0085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Thyroid Journal, 2024. Verfasst von Megumi Fujikawa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Fujikawa-Megumi Clinic, Mizutani 2-7-7, Higashi-ku, Fukuoka, Japan. Hauptthemen laut MEDLINE: Potassium Iodide, Graves Disease, Methimazole, Antithyroid Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

As thionamide is associated with various adverse effects, we re-evaluated the practical efficacy of potassium iodide (KI) therapy for Graves’ hyperthyroidism (GD).

Methods

We administered KI (mainly 100 mg/day) to 324 untreated GD patients and added methimazole (MMI) only to those remaining thyrotoxic even at 200 mg/day. When the patient became hypothyroid, MMI, if taken was stopped, then levothyroxine (LT4) was added without reducing the KI dose. Radioactive iodine (RI) therapy or thyroidectomy was performed whenever required. We evaluated the early effects of KI at 2–4 weeks and followed patients for 2 years.

Results

At 2 weeks, serum thyroid hormone levels decreased in all 324 patients. At 4 weeks, fT4, fT3, and both fT4 and fT3 levels became normal or low in 74.7%, 50.6%, and 50.6% of patients, respectively. In a cross-sectional survey over 2 years, GD was well-controlled with KI or KI + LT4 (KI-effective) in >50% of patients at all time points. Among 288 patients followed for 2 years, 42.7% remained ‘KI-effective’ throughout the 2 years (KI Group), 30.9% were well-controlled with additional MMI given for 1–24 months, and 26.4% were successfully treated with ablative therapy (mainly RI). Among ‘KI-effective’ patients at 4 weeks, 76.5% were classified into the KI Group. No patients experienced adverse effects from KI.

Conclusion

KI therapy was useful in the treatment of GD. A sufficient dose of KI was effective in >50% of GD patients from 4 weeks to 2 years, and 42.7% (76.5% of ‘KI-effective’ patients at 4 weeks) remained ‘KI-effective’ throughout the 2 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Potassium IodideGraves DiseaseMethimazoleAntithyroid AgentsHumansMaleFemaleAdultMiddle AgedFollow-Up StudiesTreatment OutcomeThyroxineCross-Sectional StudiesIodine RadioisotopesAgedThyroidectomyYoung AdultThyroid Hormones

Stichwörter der Autor:innen

Graves’ diseasehyperthyroidismiodinepotassium iodide

Substanzen

Potassium IodideMethimazoleAntithyroid AgentsThyroxineIodine RadioisotopesThyroid Hormones

Autor:innen und Institutionen

  • Fujikawa-Megumi Clinic, Mizutani 2-7-7, Higashi-ku, Fukuoka, Japan.
  • Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka, Japan.

ORCID-Profile: Megumi Fujikawa

Zitieren

APA

Fujikawa, M., & Okamura, K. (2024). Graves’ hyperthyroidism treated with potassium iodide: early response and after 2 years of follow-up. European Thyroid Journal. https://doi.org/10.1530/etj-24-0085

Vancouver

Fujikawa M, Okamura K. Graves’ hyperthyroidism treated with potassium iodide: early response and after 2 years of follow-up. European Thyroid Journal. 2024. doi:10.1530/etj-24-0085

BibTeX
@article{Fujikawa2024,
  author = {Fujikawa, Megumi and Okamura, Ken},
  title = {Graves’ hyperthyroidism treated with potassium iodide: early response and after 2 years of follow-up},
  journal = {European Thyroid Journal},
  year = {2024},
  doi = {10.1530/etj-24-0085}
}
Kostenlos starten →